The American Society of Clinical Oncology, the American Society of Hematology, and the National Comprehensive Cancer Network said they have received a key clarification from the Centers for Disease Control and Prevention on prescribing opioids to manage pain from certain conditions.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.Â
